Losmapimod did not reduce the risk of cardiovascular death, MI, or severe recurrent ischemia compared with placebo in patients with acute MI (8.1% vs 7.0%; HR 1.16; 95% CI 0.91-1.47; P=.24).
RCT (n=3,503)
double-blind
randomized
Yes
Does losmapimod reduce the composite of cardiovascular death, MI, or severe recurrent ischemia in patients hospitalized with acute myocardial infarction?
In patients with acute MI, p38 MAPK inhibition with losmapimod did not reduce major ischemic cardiovascular events, halting progression to a larger phase 3 trial.
Hazard Ratio: 1.16 (95% CI 0.91–1.47)
Absolute Event Rate: 8.1% vs 7%
p-value: p=.24
IMPORTANCE: p38 Mitogen-activated protein kinase (MAPK)-stimulated inflammation is implicated in atherogenesis, plaque destabilization, and maladaptive processes in myocardial infarction (MI). Pilot data in a phase 2 trial in non-ST elevation MI indicated that the p38 MAPK inhibitor losmapimod attenuates inflammation and may improve outcomes. OBJECTIVE: To evaluate the efficacy and safety of losmapimod on cardiovascular outcomes in patients hospitalized with an acute myocardial infarction. DESIGN, SETTING, AND PATIENTS: LATITUDE-TIMI 60, a randomized, placebo-controlled, double-blind, parallel-group trial conducted at 322 sites in 34 countries from June 3, 2014, until December 8, 2015. Part A consisted of a leading cohort (n = 3503) to provide an initial assessment of safety and exploratory efficacy before considering progression to part B (approximately 22,000 patients). Patients were considered potentially eligible for enrollment if they had been hospitalized with an acute MI and had at least 1 additional predictor of cardiovascular risk. INTERVENTIONS: Patients were randomized to either twice-daily losmapimod (7.5 mg; n = 1738) or matching placebo (n = 1765) on a background of guideline-recommended therapy. Patients were treated for 12 weeks and followed up for an additional 12 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was the composite of cardiovascular death, MI, or severe recurrent ischemia requiring urgent coronary revascularization with the principal analysis specified at week 12. RESULTS: In part A, among the 3503 patients randomized (median age, 66 years; 1036 29.6% were women), 99.1% had complete ascertainment for the primary outcome. The primary end point occurred by 12 weeks in 123 patients treated with placebo (7.0%) and 139 patients treated with losmapimod (8.1%; hazard ratio, 1.16; 95% CI, 0.91-1.47; P = .24). The on-treatment rates of serious adverse events were 16.0% with losmapimod and 14.2% with placebo. CONCLUSIONS AND RELEVANCE: Among patients with acute MI, use of losmapimod compared with placebo did not reduce the risk of major ischemic cardiovascular events. The results of this exploratory efficacy study did not justify proceeding to a larger efficacy trial in the existing patient population. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02145468.
O’Donoghue et al. (2016) conducted an RCT in acute myocardial infarction (n=3,503). losmapimod vs. placebo was evaluated on composite of cardiovascular death, MI, or severe recurrent ischemia requiring urgent coronary revascularization (HR 1.16, 95% CI 0.91-1.47, p=.24). Losmapimod did not reduce the risk of cardiovascular death, MI, or severe recurrent ischemia compared with placebo in patients with acute MI (8.1% vs 7.0%; HR 1.16; 95% CI 0.91-1.47; P=.24).